Recursion Pharmaceuticals, Inc. RXRX Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s change in deferred revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported change in deferred revenue of -$2.25M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s change in deferred revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s change in deferred revenue increased by 77.0% year-over-year, from -$9.76M to -$2.25M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s change in deferred revenue?
- Over 2 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s change in deferred revenue has grown at a 91.8% compound annual growth rate (CAGR), from -$10M to -$36.77M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.